Apitope reclaims multiple sclerosis treatment from Merck after 7 years
October 17, 2016Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis
Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …
Valeant Pharmaceutical release their latest price increases
October 17, 2016Sales and Marketing
Valeant Pharmaceutical announced, on 14 October, that their Patient Access and Pricing Committee had decided on a price range increase …
Hanmi Pharmaceutical raided over insider trading suspicions
October 17, 2016Sales and Marketing Boehringer Ingelheim, Genentech, Hanmi Pharmaceutical, south korea
At the end of September, we reported on a busy 24-hour for Hanmi Pharmaceutical, as they secured a deal with …
EMA grants conditional approval for biliary cholangitis treatment
October 17, 2016Sales and Marketing EMA, intercept, ocaliva, primary biliary cholangitis
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has voiced its approval of Intercept’s Ocaliva …
Celgene trial displays promising results for Crohn’s disease alternative treatment
October 17, 2016Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial
Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …
Kite Pharma appoints Chris Nowers as Head of Europe
October 14, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Nowers, London, kite pharma
Kite Pharma announced on 13 October that it had appointed Chris Nowers as its Head of Europe. Nowers will be …
Top Ten articles in the pharma industry this week
October 14, 2016Medical Communications news, october, pharmaceutical, top 10, top ten, top ten stories
This week has seen a lot of news regarding specific drugs going through trial and some impressive results within. Read …
Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal
October 14, 2016Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD
Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …
NICE plans new “fast-track” appraisal option
October 14, 2016Medical Communications, Sales and Marketing NHS, NICE
The National Institute for Health and Care Excellence (NICE) has proposed the introduction of a fast-track process which could make …
NICE knocks back Janssen rare disease drug
October 13, 2016Medical Communications Janssen, NICE, imbruvica
NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …
Pfizer loses UK patent infringement case over $5.1bn drug
October 13, 2016Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, patent infringement, pregabalin
Pfizer has been dealt a significant blow as the UK Court of Appeal has rejected the company’s patent infringement claims …
Nordic Nanovector announces the appointment of Joanna Horobin as Non-Executive Board Director
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nordic Nanovector, appointment, norway
Nordic Nanovector announced on 12 October that Joanna Horobin was elected to its Board as non-executive director at the company’s …
Merck KgaA foresees meeting 2018 objectives and plans for 2022
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, 2022, Germany, Merck KGaA
Speaking at its 2016 Capital Market Day about the progress it had made towards its 2018 objectives, CEO Stefan Oschmann …
Sanofi lowers Q3 sales figures from 2015
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results
Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …
New treatment for leukaemia nullifies cancer cells
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia
New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …
Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, India, US, america, sun pharmaceutical
Sun Pharmaceuticals have been forced to recall 31,762 bottles of anti-depressants from the US market after the FDA issued a …
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health
October 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle
The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Gamida Cell receives Breakthrough Therapy Designation from FDA
October 12, 2016Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma
Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
